These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28416502)

  • 21. Interim FDG-PET Imaging in Lymphoma.
    Gallamini A; Zwarthoed C
    Semin Nucl Med; 2018 Jan; 48(1):17-27. PubMed ID: 29195613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy.
    Cox MC; Ambrogi V; Lanni V; Cavalieri E; Pelliccia S; Scopinaro F; Monarca B; Marchetti P; Spiriti MA
    Leuk Lymphoma; 2012 Feb; 53(2):263-9. PubMed ID: 21846184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
    Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH
    J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interim FDG-PET/CT for Response Assessment of Lymphoma.
    Zeman MN; Akin EA; Merryman RW; Jacene HA
    Semin Nucl Med; 2023 May; 53(3):371-388. PubMed ID: 36376131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of FDG-PET in the interim evaluation of therapy response in diffuse large B-cell lymphoma.
    Ellmann A
    Transfus Apher Sci; 2013 Aug; 49(1):40-2. PubMed ID: 23769694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.
    Cherng HJ; Sargent RL; Nasta SD; Svoboda J; Schuster SJ; Mato AR; Schrank-Hacker A; Morrissette JJD; Landsburg DJ
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):673-678. PubMed ID: 30033208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
    Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
    J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
    Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.
    Baratto L; Davidzon GA; Moghbel M; Hatami N; Iagaru A; Mittra ES
    Clin Nucl Med; 2018 Jan; 43(1):1-8. PubMed ID: 29076913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
    Terasawa T; Lau J; Bardet S; Couturier O; Hotta T; Hutchings M; Nihashi T; Nagai H
    J Clin Oncol; 2009 Apr; 27(11):1906-14. PubMed ID: 19273713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour necrosis as assessed with
    Kahle XU; Hovingh M; Noordzij W; Seitz A; Diepstra A; Visser L; van den Berg A; van Meerten T; Huls G; Boellaard R; Kwee TC; Nijland M
    Eur Radiol; 2019 Nov; 29(11):6018-6028. PubMed ID: 31028445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
    Zhang YY; Song L; Zhao MX; Hu K
    Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
    Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
    J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis.
    Torka P; Pederson LD; Knopp MV; Poon D; Zhang J; Kahl BS; Higley HR; Kelloff G; Friedberg JW; Schwartz LH; Wilson WH; Leonard JP; Bartlett NL; Schöder H; Ruppert AS
    Cancer Med; 2023 Apr; 12(7):8211-8217. PubMed ID: 36799072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.
    Chow A; Phillips M; Siew T; Cull G; Augustson B; Ward M; Joske D
    Intern Med J; 2013 Aug; 43(8):932-9. PubMed ID: 23692386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy.
    Hoppe BS; McCarten KM; Pei Q; Kessel S; Alazraki A; Mhlanga JC; Lai HA; Eutsler E; Hodgson DC; Roberts KB; Charpentier AM; Keller FG; Voss SD; Wu Y; Cho SY; Kelly KM; Castellino SM
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1025-1030. PubMed ID: 36868525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.